- Home
- IAUX vs ADAP Comparison
IAUX vs ADAP Comparison
Compare IAUX & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- ADAP
- Stock Information
- Founded
- IAUX 2020
- ADAP 2008
- Country
- IAUX United States
- ADAP United Kingdom
- Employees
- IAUX N/A
- ADAP N/A
- Industry
- IAUX
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- IAUX
- ADAP Health Care
- Exchange
- IAUX Nasdaq
- ADAP Nasdaq
- Market Cap
- IAUX 261.9M
- ADAP 212.3M
- IPO Year
- IAUX N/A
- ADAP 2015
- Fundamental
- Price
- IAUX $0.51
- ADAP $0.59
- Analyst Decision
- IAUX
- ADAP Strong Buy
- Analyst Count
- IAUX 0
- ADAP 4
- Target Price
- IAUX N/A
- ADAP $2.79
- AVG Volume (30 Days)
- IAUX 7.2M
- ADAP 2.2M
- Earning Date
- IAUX 11-12-2024
- ADAP 11-13-2024
- Dividend Yield
- IAUX N/A
- ADAP N/A
- EPS Growth
- IAUX N/A
- ADAP N/A
- EPS
- IAUX N/A
- ADAP N/A
- Revenue
- IAUX $52,944,000.00
- ADAP $175,041,000.00
- Revenue This Year
- IAUX N/A
- ADAP $204.91
- Revenue Next Year
- IAUX $158.96
- ADAP N/A
- P/E Ratio
- IAUX N/A
- ADAP N/A
- Revenue Growth
- IAUX 30.02
- ADAP 146.27
- 52 Week Low
- IAUX $0.34
- ADAP $0.47
- 52 Week High
- IAUX $1.88
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- IAUX 34.03
- ADAP 37.19
- Support Level
- IAUX $0.48
- ADAP $0.58
- Resistance Level
- IAUX $0.66
- ADAP $0.63
- Average True Range (ATR)
- IAUX 0.04
- ADAP 0.04
- MACD
- IAUX 0.00
- ADAP -0.00
- Stochastic Oscillator
- IAUX 6.42
- ADAP 26.74
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.